1558 — Yichang Hec Changjiang Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapNeutral

Market Cap
HK$10.75bn
Enterprise Value
HK$11.63bn
Revenue
CNY3.72bn

Annual income statement for Yichang Hec Changjiang Pharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,348	914	3,745	6,295	3,724
Cost of Revenue
Gross Profit	1,997	484	2,846	4,986	2,794
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,093	1,337	3,424	3,940	3,049
Operating Profit	1,255	-423	321	2,354	674
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	1,010	-667	39.4	2,127	577
Provision for Income Taxes
Net Income After Taxes	837	-588	49.2	1,856	483
Minority Interest
Net Income Before Extraordinary Items
Net Income	839	-588	76.6	1,993	483
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	590	-588	76.6	1,993	483
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.538	-0.635	0.301	2.75	0.621
Dividends per Share
Special Dividends per Share